Go to Sitemap
James Whitlock
Research Positions
Senior Associate Scientist, Translational Medicine
Biography
Experience
- 2010–Present: Professor of Paediatrics, University of Toronto, Toronto, ON
- 2006–2010: Professor of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN
- 1997–2010: Craig-Weaver Professor of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN
- 1997–2006: Associate Professor, Pediatric Hematology/Oncology, Vanderbilt University School of Medicine, Nashville, TN
- 1991–1997: Assistant Professor, Pediatric Hematology/Oncology, Vanderbilt University School of Medicine, Nashville, TN
- 2011–Present: Director, Garron Family Cancer Centre, The Hospital for Sick Children, Toronto, ON
- 2010–Present: Women's Auxiliary Millennium Chair in Haematology/Oncology, The Hospital for Sick Children, Toronto, ON
- 2010–Present: Division Head, Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON
- 1997–2010: Division Head, Pediatric Hematology/Oncology, Vanderbilt University School of Medicine, Nashville, TN
- 1991–1997: Staff Physician, Vanderbilt University Hospital/ Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN
- 2019–Present: Senior Associate Scientist, Translational Medicine, The Hospital for Sick Children Research Institute, Toronto, ON
- 2010–2019: Senior Associate Scientist, Child Health Evaluative Sciences, The Hospital for Sick Children Research Institute, Toronto, ON
Research
Dr. Whitlock’s research interests include the biology and treatment of childhood acute leukemias, the development of new drugs for the treatment of childhood cancers, and the biology and treatment of histiocytic disorders. He was the inaugural Vice-Chair for New Agents and Relapse studies for the Acute Lymphoblastic Leukemia Committee of the Children’s Oncology Group (COG), and is current or past Chair or Vice-Chair of several COG clinical trials. He is the lead investigator for an international phase I trial of nelarabine combination therapy for relapsed T-cell ALL (T2008-002: NECTAR) through the Therapeutic Advances in Childhood Leukemia (TACL) consortium, and served two terms as the first chair of TACL’s Steering & Prioritization Committee. He is a past President of the Histiocyte Society, an international scientific organization which supports research in, and conducts clinical trials for, histiocytic disorders. He is the current Chair of C17, the national organization for Canadian childhood cancer and blood disorder centres.